Weekly Wrap

研报英文原文证据摘录

Weekly Wrap

EUROPE | Pharmaceuticals EquityJulyResearch18, 2026

Weekly Wrap Key Research Published:

AC Immune: AC Immune Takes AAICWe provide a short summary of key updates and additional tidbits across •

our European Pharma, Biopharma, and Biotech coverage. • Alk-Abello: Expecting Guidance

Upgrade Cycle to Continue & Baking in

Higher Rebates

AstraZeneca licenses Dizal's oral EGFR pill Zegfrovy: Zegfrovy (sunvozertinib) is an oral

Bayer: Spinning ain't easyEGFR inhibitor already approved in the US and China for advanced NSCLC patients with EGFR •

Camurus: 2Q Revs and Profits Bigexon 20 insertion mutations who have progressed after platinum chemo. The only current •

Beats; Outlook Reiterated; SORENTO1L option in this space is J&J's intravenous Rybrevant plus chemo. Under the terms, AZN

194 Events 4Q26E & Resubmission ofwill pay $600m upfront, up to $900m in development and commercial milestones, plus tiered

Oclaiz NDA Earlier Than Expected, forroyalties, acquiring an asset that generated c.$83m in 2025 sales. While the current opportunity

PDUFA Date 18 Decis in the post-platinum setting, the larger commercial potential lies in 1L treatment, where

Genmab: JNJ Results Show DarzalexPhase III WU-KONG28 showed superior efficacy versus chemotherapy (mPFS 10.3 vs 7.5 •

months, ORR 68% vs 35%). Dizal has already filed for 1L approval in both the US and China and 2Q Beat; Clinical Catalysts Remain in

received Breakthrough Therapy Designation from the FDA. Strategically, the deal complements Focus

GSK: Truly (£40bn), Madly (qualityAZN's established leadership in EGFR-mutant lung cancer with Tagrisso, provides a potentially •

more convenient oral alternative to J&J's regimen, and represents AZN's second China-derived BD), Deeply (oncology portfolio) &